{"transactions":[{"id":740326,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Stock options (Right to buy)","published_at":"2026-06-12T17:09:52.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":true,"shares":31235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares sold in this transaction were fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.82,"expiration_date":"2035-05-31","underlying":"Common Stock","underlying_shares":31235},"source":{"system":"sec-edgar","filing":"0001193125-26-269694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526269694/ownership.xml","form_type":"4"}},{"id":740325,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Stock options (Right to buy)","published_at":"2026-06-12T17:09:52.000Z","date":"2026-06-11","kind":"exercise","planned":true,"acquired":true,"shares":22515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares sold in this transaction were fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.82,"expiration_date":"2035-05-31","underlying":"Common Stock","underlying_shares":22515},"source":{"system":"sec-edgar","filing":"0001193125-26-269694","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526269694/ownership.xml","form_type":"4"}},{"id":740324,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2026-06-12T17:09:52.000Z","date":"2026-06-12","kind":"sale","planned":true,"acquired":false,"shares":31235,"price":18.14,"value":566602.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date."}],"balance_after":60885,"source":{"system":"sec-edgar","filing":"0001193125-26-269694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526269694/ownership.xml","form_type":"4"}},{"id":740323,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2026-06-12T17:09:52.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":true,"shares":31235,"price":13.82,"value":431667.7,"ownership":{"direct":true},"balance_after":92120,"source":{"system":"sec-edgar","filing":"0001193125-26-269694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526269694/ownership.xml","form_type":"4"}},{"id":740322,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2026-06-12T17:09:52.000Z","date":"2026-06-11","kind":"sale","planned":true,"acquired":false,"shares":34280,"price":18,"value":617040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date."}],"balance_after":60885,"source":{"system":"sec-edgar","filing":"0001193125-26-269694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526269694/ownership.xml","form_type":"4"}},{"id":740321,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2026-06-12T17:09:52.000Z","date":"2026-06-11","kind":"exercise","planned":true,"acquired":true,"shares":22515,"price":13.82,"value":311157.3,"ownership":{"direct":true},"balance_after":95165,"source":{"system":"sec-edgar","filing":"0001193125-26-269694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526269694/ownership.xml","form_type":"4"}},{"id":916285,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Stock Options (Right to buy)","published_at":"2026-02-06T16:50:19.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":144700,"price":20.43,"value":2956221.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":144700,"derivative":{"exercise_price":20.43,"expiration_date":"2036-02-04","underlying":"Common Stock","underlying_shares":144700},"source":{"system":"sec-edgar","filing":"0001193125-26-041334","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526041334/ownership.xml","form_type":"4"}},{"id":916284,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2026-02-06T16:50:19.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company."}],"balance_after":95165,"source":{"system":"sec-edgar","filing":"0001193125-26-041334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526041334/ownership.xml","form_type":"4"}},{"id":916283,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2026-02-06T16:50:19.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of restricted stock units (\"RSUs\"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested."}],"balance_after":59165,"source":{"system":"sec-edgar","filing":"0001193125-26-041334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000119312526041334/ownership.xml","form_type":"4"}},{"id":1143302,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":38902,"kind":"person","name":"Botwood Nicholas A.J.","position":1,"cik":"0002066784","reported_name":"Botwood Nicholas A.J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Head of R&D, CMO"}}],"security":"Common Stock","published_at":"2025-05-19T16:03:03.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":11765,"price":8.995,"value":105826.175,"ownership":{"direct":true},"balance_after":35165,"source":{"system":"sec-edgar","filing":"0000950170-25-074301","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2066784/000095017025074301/ownership.xml","form_type":"4"}}]}